These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21460720)

  • 1. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies.
    Falutz J
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):255-60. PubMed ID: 21460720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
    Falutz J; Allas S; Blot K; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
    N Engl J Med; 2007 Dec; 357(23):2359-70. PubMed ID: 18057338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors and HIV disease.
    Fedele F; Bruno N; Mancone M
    AIDS Rev; 2011; 13(2):119-29. PubMed ID: 21587343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.
    Deeks SG
    Top HIV Med; 2009; 17(4):118-23. PubMed ID: 19890183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV medications: an update and review of metabolic complications.
    Hester EK
    Nutr Clin Pract; 2012 Feb; 27(1):51-64. PubMed ID: 22307491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAART-associated body habitus and metabolic changes, Part 2.
    Liss M; Boyle BA
    AIDS Read; 2000 Dec; 10(12):688-91. PubMed ID: 11189733
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
    Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
    Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy--an observational study.
    Padmapriyadarsini C; Swaminathan S; Karthipriya MJ; Narendran G; Menon PA; Thomas BE
    J Assoc Physicians India; 2010 Jun; 58():375-7. PubMed ID: 21125779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.